Germany · Delayed Price · Currency is EUR Exasol AG Earnings Call Transcripts
Fiscal Year 2026
-
ARR declined 3.5% year-over-year but improved sequentially, with churn rates normalizing and new logo wins increasing. Revenue fell due to the absence of a prior one-time deal, while recurring revenue and liquidity remained stable. Guidance for ARR growth and EBITDA is confirmed.
Fiscal Year 2025
-
Revenue grew 5.6% to EUR 49.9M, with EBITDA more than doubling and net income at EUR 3.1M. ARR declined 8% due to early churn in non-focus industries, but focus verticals saw strong upsells and partnerships. 2026 guidance targets mid single-digit ARR growth and stable profitability.
-
Revenue grew 9% year-over-year to EUR 31.7 million, but ARR declined 4% due to churn in non-focus verticals. Focus verticals now account for 70% of ARR, and the MariaDB partnership is expected to drive growth in 2026. EBITDA guidance was raised to EUR 3.5–4 million.
-
Revenue grew 9% to €31.7M, but ARR declined 4% due to high churn in non-focus verticals. Focus verticals showed strong growth and low churn, with a new MariaDB partnership set to drive growth from 2026. EBITDA and liquidity remain strong, and guidance was adjusted accordingly.
-
Revenue rose 10.8% to EUR 21.5 million in H1 2025, with EBITDA and net income both up sharply year-over-year. Focus verticals now account for 69% of ARR, and strong liquidity supports ongoing investment in AI and regulated industry solutions.
-
Q1 2025 delivered strong revenue and profitability growth, driven by focus verticals and one-off hardware/service deals, despite a decline in total ARR from non-focus vertical churn. Guidance for mid-single-digit ARR and revenue growth with higher EBITDA is confirmed, supported by robust liquidity and a strategic shift toward regulated industries.
Fiscal Year 2024
-
Achieved profitability in 2024 with EUR 2 million EBITDA and 13% revenue growth, driven by focus on regulated verticals. Expect mid-single digit growth and 50%+ EBITDA increase in 2025, with continued portfolio shift toward finance and healthcare.
-
Profitability achieved for the first time in recent years, with EBITDA of EUR 1 million for the first nine months and full-year guidance of EUR 1.5–2 million. ARR grew 12% year-over-year, driven by focus on regulated and hybrid/on-premise customers, while churn remains elevated in non-core verticals.
-
First half 2024 saw a return to profitability with positive EBITDA and strong cash flow, despite elevated churn in EMEA. ARR and revenue grew year-over-year, and guidance for 2024 remains unchanged, with further AI-driven product innovation and stable headcount expected.